Clinical Report: Clinical Trial Update January 2026
Overview
This report summarizes ongoing clinical trials targeting age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and uveitis. Notable studies include evaluations of various investigational therapies, including ONL1204 and SAR446597, highlighting advancements in treatment options.
Background
The management of AMD, DME, RVO, and uveitis remains a critical focus in ophthalmology due to their significant impact on vision and quality of life. Recent guidelines emphasize the importance of timely intervention and the use of anti-VEGF therapies as first-line treatments. Ongoing clinical trials are essential for evaluating new therapies and improving patient outcomes.
Data Highlights
No numerical data available in the source material.
Key Findings
Evaluation of OLX10212 in neovascular AMD has been completed.
ONL1204 is being studied for efficacy and safety in geographic atrophy associated with AMD.
A phase 2 study is assessing dapagliflozin for safety and efficacy in geographic atrophy secondary to AMD.
SAR446597 is under investigation for its safety and efficacy in geographic atrophy secondary to AMD.
ABBV-6628 is being evaluated for pharmacokinetics and exploratory efficacy in geographic atrophy secondary to AMD.
Clinical Implications
Healthcare professionals should stay informed about the latest clinical trials and emerging therapies for AMD, DME, RVO, and uveitis. Participation in clinical trials may provide patients access to novel treatments and contribute to the advancement of care in these conditions.
Conclusion
The ongoing clinical trials reported in January 2026 reflect a commitment to advancing treatment options for retinal diseases. Continued research is vital for improving patient outcomes and refining therapeutic strategies.
Joseph P. Shovlin, OD, FAAO, reviewed diagnosis, management, and emerging evidence related to chronic herpetic eye disease prevention at Optometry's Meeting 2026.
The movement of immune cells through the retinal vasculature has long been inferred from laboratory models. Now, advances in imaging are allowing clinicians to observe these processes directly. At the 2026 meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Denver, Richard B. Rosen, MD, ScD(hon), FACS, FASRS, FARVO, described early clinical work using adaptive optics scanning laser ophthalmoscopy (AOSLO) to visualize leukocyte trafficking in vivo.
